Tag
This secondary analysis of the SirPAD trial shows that sirolimus-coated balloon angioplasty significantly reduces 1-year target-lesion revascularization rates compared to uncoated balloons in femoropopliteal artery disease patients without
This study compares long-term outcomes of endovascular versus open bypass interventions for femoropopliteal disease in patients with claudication, finding similar rates of major adverse limb events and progression to critical limb ischemia
A validated polygenic risk score (PRS) independently predicts peripheral artery disease (PAD) and major adverse limb events (MALE) in patients with cardiometabolic disease, adding modest but significant predictive value beyond traditional c
Bempedoic acid reduces the risk of major adverse limb and cardiovascular events in statin-intolerant patients with peripheral artery disease, illustrating its potential to enhance vascular risk management.
This national study identifies key factors linked to 30-day nonelective readmissions after open lower extremity revascularization, highlighting stable readmission rates despite reduced procedure volume and the need for standardized discharg
This article reviews recent advances in the medical management of peripheral artery disease, emphasizing comprehensive risk factor control, novel pharmacotherapies, and individualized approaches to improve cardiovascular and limb outcomes i
In Medicare patients undergoing femoropopliteal revascularization, drug-coated devices were not associated with higher long-term mortality, supporting the safety of paclitaxel-coated technology after years of regulatory concern.
This review synthesizes evidence that intramuscular adipose tissue (IMAT) accumulation, driven by fibroadipogenic progenitors, is a primary driver of limb dysfunction in PAD/CLTI, identifying IMAT as a novel therapeutic target.
A VOYAGER-PAD sub-analysis reveals that patients with prior limb revascularization are at significantly higher risk for adverse events but derive a greater relative benefit from low-dose rivaroxaban plus aspirin.
The PERMET randomized clinical trial found that metformin did not improve the 6-minute walk distance or secondary walking outcomes in patients with peripheral artery disease without diabetes, suggesting no benefit for functional impairment
A post hoc analysis of the STRIDE trial reveals that once-weekly semaglutide 1.0 mg significantly improves walking distance and quality of life in both men and women with type 2 diabetes and peripheral artery disease, despite notable differ
A large-scale cohort study reveals that while rivaroxaban and apixaban offer similar protection against limb events and stroke in patients with AF and PAD, rivaroxaban is associated with a 55% higher risk of major bleeding, suggesting apixa
In pooled analyses of six TIMI trials (n=68,816), a validated PAD polygenic risk score was independently associated with prevalent PAD (OR per 1-SD 1.15) and incident major adverse limb events (HR per 1-SD 1.30), but added only modest impro
The PERMET randomized, double-blind trial found that 6 months of metformin did not improve 6-minute walk distance or other functional endpoints in people with lower extremity peripheral artery disease (PAD) without diabetes.
The SWEDEPAD 2 trial reveals that paclitaxel-coated devices do not improve quality of life at 1 year and raise concerns about increased 5-year mortality in patients with intermittent claudication undergoing lower limb revascularisation.
A supervised treadmill exercise program lasting over 6 weeks is essential to achieve significant walking improvements in peripheral artery disease, with peak patient-reported benefits observed at 12 weeks but diminishing by 26 weeks.
The STRIDE trial demonstrates that once-weekly semaglutide significantly enhances walking capacity in patients with symptomatic peripheral artery disease and type 2 diabetes, irrespective of baseline diabetes duration, BMI, HbA1c levels, or
Elevated lipoprotein(a) levels significantly predict incident peripheral artery disease and carotid stenosis, as well as progression to major limb events, underscoring its value as a prognostic biomarker for extracoronary atherosclerotic va
Discover the crucial early signs of vascular blockage in hands and feet, simple self-check methods, and expert insights to protect your circulatory health effectively.
A landmark UK Biobank study demonstrates that elevated lipoprotein(a) independently predicts both the onset and progression of peripheral artery disease and carotid stenosis, beyond traditional cardiovascular risk factors.
